Lead: GLP-1 receptor agonist treatment and health outcomes in methadone-treated patients with opioid use disorder and diabetes
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Lead: GLP-1 receptor agonist treatment and health outcomes in methadone-treated patients with opioid use disorder and diabetes
-
Narrated by:
-
By:
A retrospective comparison of two state-funded smartphone-based contingency management programs with different incentives
Drug and Alcohol Dependence
This retrospective study compared outcomes for patients with stimulant use disorder enrolled in a smartphone-based contingency management program based on the amount of total incentives possible, either $75 (“low-value”) or $599 (“moderate-value”). The low-value program was based in New Jersey, funded through SAMHSA (which limited reimbursement to $75/patient at the time of implementation, which has since been increased), and rewarded completing drug testing, attending counseling visits, and completing CBT modules rather than abstinence over 16 weeks. The moderate-value program was funded by West Virginia’s Medicaid managed care organizations, lasted up to 26 weeks, and largely rewarded negative drug screening results, with additional rewards for counseling and CBT modules. Patients in the moderate-value program submitted significantly higher rates of negative substance tests (36%, with an average of 3.2 negative tests) compared to those in the low-value group (24.7%, with an average of 24.8 negative tests).
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM